Ye Ziliang, Lu Haili, Su Qiang, Xian Xinhua, Li Lang
Department of Cardiology, The First Affiliated Hospital of Guangxi Medical University, Guangxi Cardiovascular Institute, Nanning, Guangxi, China.
Guangxi Medical University, Nanning, Guangxi, China.
Oncotarget. 2017 Sep 28;8(54):92366-92374. doi: 10.18632/oncotarget.21310. eCollection 2017 Nov 3.
Our purpose was to assess the effect of ligustrazine in the prevention of contrast-induced nephropathy (CIN) in patients with unstable angina (UA).
148 patients with UA undergoing coronary angiography and/or percutaneous coronary intervention (PCI) were selected for observation; the patients were divided into a control group (group A, n=74) and a ligustrazine group (group B, n=74). Group A was given routine treatment, while group B was given routine treatment combined with ligustrazine. Serum creatinine (Scr), cystatin C and glomerular filtration rate (eGFR) concentrations were measured before and 1 day, 2 days and 3 days after treatment, and the incidence of contrast-induced nephropathy (CIN) and major cardiovascular events (MACE) were observed in both groups.
The Scr, Cystatin C and eGRF levels in group B were better than in group A after 1 day (OR: 2.64, 95% CI: 2.47-4.98; OR: 2.66, 95% CI: 2.62-5.77; OR: 4.02, 95% CI: 3.02-5.53, respectively), 2 days (OR: 3.58, 95% CI: 2.41-4.92; OR: 2.92, 95% CI: 2.83-5.02; OR: 3.28, 95% CI: 3.24-5.14, respectively) and 3 days of treatment (OR: 3.26, 95% CI: 2.17-4.35; OR: 2.85, 95% CI: 2.26-4.02; OR: 3.19, 95% CI: 2.53-4.34, respectively). The incidence of CIN (9.26% vs 16.67%) and MACE (7.41% vs 18.51%) of group B were significantly lower than in group A (P<0.05).
Our study suggests that ligustrazine can reduce CIN and MACE in patients with UA when undergoing coronary angiography and/or PCI.
我们的目的是评估川芎嗪对不稳定型心绞痛（UA）患者造影剂肾病（CIN）的预防作用。
选取148例接受冠状动脉造影和/或经皮冠状动脉介入治疗（PCI）的UA患者进行观察；将患者分为对照组（A组，n = 74）和川芎嗪组（B组，n = 74）。A组给予常规治疗，而B组给予常规治疗联合川芎嗪。在治疗前及治疗后1天、2天和3天测量血清肌酐（Scr）、胱抑素C和肾小球滤过率（eGFR）浓度，并观察两组造影剂肾病（CIN）和主要心血管事件（MACE）的发生率。
治疗1天后（OR分别为：2.64，95%CI：2.47 - 4.98；OR：2.66，95%CI：2.62 - 5.77；OR：4.02，95%CI：3.02 - 5.53）、2天后（OR分别为：3.58，95%CI：2.41 - 4.92；OR：2.92，95%CI：2.83 - 5.02；OR：3.28，95%CI：3.24 - 5.14）和3天后（OR分别为：3.26，95%CI：2.17 - 4.35；OR：2.85，95%CI：2.26 - 4.02；OR：3.19，95%CI：2.53 - 4.34），B组的Scr、胱抑素C和eGRF水平均优于A组。B组的CIN发生率（9.26%对vs ）和MACE发生率（7.41%对vs 18.51%）显著低于A组（P<0.05）。
我们的研究表明，川芎嗪可降低UA患者在接受冠状动脉造影和/或PCI时的CIN和MACE发生率。
